Details

Autor(en) / Beteiligte

• Thursz, Mark R
• Richardson, Paul
• Allison, Michael
• Austin, Andrew
• Bowers, Megan
• Day, Christopher P
• Downs, Nichola
• Gleeson, Dermot
• MacGilchrist, Alastair
• Grant, Allister
• Hood, Steven
• Masson, Steven
• McCune, Anne
• Mellor, Jane
• O’Grady, John
• Patch, David
• Ratcliffe, Ian
• Roderick, Paul
• Stanton, Louise
• Vergis, Nikhil
• Wright, Mark
• Ryder, Stephen
• Forrest, Ewan H

Titel

Prednisolone or Pentoxifylline for Alcoholic Hepatitis

Ist Teil von

• The New England journal of medicine, 2015-04, Vol.372 (17), p.1619-1628

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this randomized trial in patients hospitalized with alcoholic hepatitis, pentoxifylline did not improve survival. The 28-day survival advantage in patients treated with prednisolone did not reach significance and was not sustained at 90 days or 1 year. Alcoholic hepatitis is a distinct manifestation of alcoholic liver disease that is characterized by jaundice and liver failure. This condition develops in persons with a history of prolonged and heavy alcohol use. 1 The severity of alcoholic hepatitis is conventionally defined by Maddrey’s discriminant function, which is calculated as 4.6×(patient’s prothrombin time in seconds−control’s prothrombin time in seconds)+patient’s serum bilirubin level in milligrams per deciliter; a value of 32 or higher indicates severe alcoholic hepatitis that carries an adverse prognosis, with mortality of 20 to 30% within 1 month after presentation and 30 to 40% within 6 months after presentation. 2 A . . .